Home/Filings/4/0000929638-25-001950
4//SEC Filing

Cormorant Asset Management, LP 4

Accession 0000929638-25-001950

CIK 0001637715other

Filed

May 18, 8:00 PM ET

Accepted

May 19, 5:33 PM ET

Size

14.4 KB

Accession

0000929638-25-001950

Insider Transaction Report

Form 4
Period: 2025-05-15
Chen Bihua
10% Owner
Transactions
  • Sale

    Class A Common Stock

    2025-05-15$1.85/sh1,813,439$3,363,0230 total(indirect: See Footnote)
Transactions
  • Sale

    Class A Common Stock

    2025-05-15$1.85/sh1,813,439$3,363,0230 total(indirect: See Footnote)
Transactions
  • Sale

    Class A Common Stock

    2025-05-15$1.85/sh1,813,439$3,363,0230 total(indirect: See Footnote)
Transactions
  • Sale

    Class A Common Stock

    2025-05-15$1.85/sh1,813,439$3,363,0230 total(indirect: See Footnote)
Transactions
  • Sale

    Class A Common Stock

    2025-05-15$1.85/sh1,813,439$3,363,0230 total(indirect: See Footnote)
Transactions
  • Sale

    Class A Common Stock

    2025-05-15$1.85/sh1,813,439$3,363,0230 total(indirect: See Footnote)
Footnotes (2)
  • [F1]Cormorant Asset Management, LP serves as the investment manager to Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund III, LP ("Fund III"), Cormorant Private Healthcare Fund IV, LP ("Fund IV") and Cormorant Private Healthcare Fund V, LP ("Fund V"). Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC serve as the general partners of the Master Fund, Fund III, Fund IV and Fund V, respectively. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant Asset Management, LP.
  • [F2]Represents the weighted average sale price of Class A Common Stock (the "shares") sold in a series of open market transactions on the transaction date ranging from $1.85 to $2.03 per share. The Reporting Persons undertake to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each price.

Documents

1 file

Issuer

OnKure Therapeutics, Inc.

CIK 0001637715

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001583977

Filing Metadata

Form type
4
Filed
May 18, 8:00 PM ET
Accepted
May 19, 5:33 PM ET
Size
14.4 KB